Gut Liver.
2025 May;19(3):299-300. 10.5009/gnl250154.
Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- KMID: 2568155
- DOI: http://doi.org/10.5009/gnl250154
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study
- Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure
- PKconverter: R package to convert the pharmacokinetic parameters
- Advances in ulcerative colitis therapy
- Optic Neuritis after Infliximab Treatment in a Patient with Ulcerative Colitis
